CLINICAL_TRIALS
withdrawal
· 2013-05-30
Clinical Trial Update: Open Label Study to Access Flurpiridaz F18 in PET MPI Verses SPECT MPI [Phase 3]
Summary
A Phase 3 open-label trial evaluating Flurpiridaz F-18 PET MPI versus SPECT MPI for coronary artery disease has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Lantheus Medical Imaging | Conditions: Coronary Artery Disease | Phase 3 | Status: WITHDRAWN